Found 3 results
Filters: Author is H. Ozyurt  [Clear All Filters]
S. Sahin, Aydogan, L., Benli, I., and Ozyurt, H., Distribution of HLA-B27 and CYP2D6*4 mutations in the middle Black Sea area (Tokat) of Turkey, vol. 10, pp. 3987-3991, 2011.
Arnett FC (1997). Ankylosing Spondylitis. In: Arthritis and Allied Conditions. A Textbook of Rheumatology (Koopman WJ, ed.). Williams and Wilkins, Baltimore, 1197-1208.   Aydin M, Hatirnaz O, Erensoy N and Ozbek U (2005). CYP2D6 and CYP1A1 mutations in the Turkish population. Cell Biochem. Funct. 23: 133-135. PMid:15648054   Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, et al. (1999). Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin. Pharmacol. Ther. 66: 185-192. PMid:10460072   Ball EJ and Khan MA (2001). HLA-B27 polymorphism. Joint Bone Spine 68: 378-382.   Beyeler C, Armstrong M, Bird HA, Idle JR, et al. (1996). Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Ann. Rheum. Dis. 55: 66-68. PMid:8572738 PMCid:1010085   Bradford LD (2002). CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3: 229-243. PMid:11972444   Breban M, Hacquard-Bouder C and Falgarone G (2004). Animal models of HLA-B27-associated diseases. Curr. Mol. Med. 4: 31-40. PMid:15011957   Brewerton DA, Hart FD, Nicholls A, Caffrey M, et al. (1973). Ankylosing spondylitis and HL-A 27. Lancet 1: 904-907.   Brown MA (2006). Non-major-histocompatibility-complex genetics of ankylosing spondylitis. Best Pract. Res. Clin. Rheumatol. 20: 611-621. PMid:16777586   Brown MA, Edwards S, Hoyle E, Campbell S, et al. (2000). Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Hum. Mol. Genet. 9: 1563-1566. PMid:10861282   Buhler S and Sanchez-Mazas A (2011). HLA DNA sequence variation among human populations: molecular signatures of demographic and selective events. PLoS One 6: e14643. PMid:21408106 PMCid:3051395   Edwards JC, Bowness P and Archer JR (2000). Jekyll and Hyde: the transformation of HLA-B27. Immunol. Today 21: 256-260.   Gjerde J, Hauglid M, Breilid H, Lundgren S, et al. (2008). Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann. Oncol. 19: 56-61. PMid:17947222   Gul A, Uyar FA, Inanc M, Ocal L, et al. (2002). A weak association of HLA-B*2702 with Behcet's disease. Genes Immun. 3: 368-372. PMid:12209364   Gunal EK, Sarvan FO, Kamali S, Gul A, et al. (2008). Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey. Joint Bone Spine 75: 299-302. PMid:18424159   Ingelman-Sundberg M (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5: 6-13. PMid:15492763   Ingelman-Sundberg M, Sim SC, Gomez A and Rodriguez-Antona C (2007). Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116: 496-526. PMid:18001838   Khan MA (1995). HLA-B27 and its subtypes in world populations. Curr. Opin. Rheumatol. 7: 263-269. PMid:7547102   Khan MA (2010). Remarkable polymorphism of HLA-B27: an ongoing saga. Curr. Rheumatol. Rep. 12: 337-341. PMid:20683684   Koseler A, Ilcol YO and Ulus IH (2007). Frequency of mutated allele CYP2D6*4 in the Turkish population. Pharmacology 79: 203-206. PMid:17374963   Ma MK, Woo MH and McLeod HL (2002). Genetic basis of drug metabolism. Am. J. Health Syst. Pharm. 59: 2061-2069. PMid:12434718   Olivieri I, Barozzi L, Padula A, De Matteis M, et al. (1998). Clinical manifestations of seronegative spondylarthropathies. Eur. J. Radiol. 27 (Suppl 1): S3-S6.   Reveille JD (2006). Major histocompatibility genes and ankylosing spondylitis. Best Pract. Res. Clin. Rheumatol. 20: 601-609. PMid:16777585   Stanevicha V, Eglite J, Zavadska D, Sochnevs A, et al. (2010). HLA B27 allele types in homogeneous groups of juvenile idiopathic arthritis patients in Latvia. Pediatr. Rheumatol. Online J. 8: 26. PMid:20946671 PMCid:2964715   Taurog JD (1997). Seronegative Spondyloarthropathies. Epidemiology, Pathology and Pathogenesis. In: Primeron the Rheumatic Disease (Klippel JH, ed.). Arthritis Foundation, Atlanta, 180-183.   Taurog JD (2009). Animal models of spondyloarthritis. Adv. Exp. Med. Biol. 649: 245-254. PMid:19731634   Taurog JD and Lipsky PE (1998). Ankylosing Spondylitis, Reactive Arthritis, and Undifferentiated Spondyloarthropathy. In: Harrison's Principles of Internal Medicine (Fauci AS, Isselbacher KJ, Braunwald E, Wilson JD, et al., eds.). McGraw-Hill Press, New York, 1904-1906.   Tay-Kearney ML, Schwam BL, Lowder C, Dunn JP, et al. (1996). Clinical features and associated systemic diseases of HLA-B27 uveitis. Am. J. Ophthalmol. 121: 47-56. PMid:8554080   Thomas GP and Brown MA (2010). Genetics and genomics of ankylosing spondylitis. Immunol. Rev. 233: 162-180. PMid:20192999   Van der Linden S, Van der Heijde D and Braun J (2005). Ankylosing Spondilitis. In: Kelley's Textbook of Rheumatology (Haris ED, Budd RC, Firestein GS, Genovese MC, et al., eds.). 7th edn. Elsevier Saunders, Philadelphia, 1125-1141.   Van der Unden (1997). Ankylosing Spondylitis. In: Texbook of Rheumatology (Kelley WN, Harris ED, Ruddy S and Sledge CB, eds.). W.B. Saunders Company, Philadelphia, 969-982.   Wagner T, Oberkanins C, Weinmayr B, Helmberg W, et al. (1998). HLA-B*27 typing by group-specific hybridization in microtiter plates. Tissue Antigens 52: 175-178. PMid:9756406   Zanger UM, Turpeinen M, Klein K and Schwab M (2008). Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 392: 1093-1108. PMid:18695978